Q-omics provides the consensus-scored CCDC136 profile across patient tissues and cancer cell-line models. CCDC136 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CCDC136 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, CCDC136 RNA expression shows 17,690 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, BLCA, and UVM as cancer lineages where CCDC136 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC136 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC136 survival associations across molecular data types. CCDC136 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC136 RNA expression–survival associations across cancer types. High CCDC136 expression shows unfavorable associations in KIRC, COAD, STAD and MESO, but favorable associations in BRCA and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for CCDC136 RNA expression.
This table summarizes CCDC136 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC136. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC136 shows lower tumor expression in BLCA, UCEC, BRCA, THCA and READ and higher tumor expression in KIRP. The BLCA box plot shows higher CCDC136 RNA expression in normal versus tumor tissue (log2 FC = −3.140, t-test p = .001).
This table shows molecular features associated with CCDC136 in patient tissues and cancer cell lines. In patient samples, CCDC136 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC136 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
